Stock UTHR UNITED THERAPEUTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
258.1 USD +1.17% Intraday chart for United Therapeutics Corporation +9.40% +17.39%
05:48pm UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating MT
03:59pm Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,865 6,746 9,731 12,674 10,333 11,320 - -
Enterprise Value (EV) 1 3,977 5,711 9,637 12,513 8,039 8,839 7,385 6,171
P/E ratio -36.9 x 13.2 x 21.5 x 18.5 x 11.1 x 10.4 x 9.63 x 9.55 x
Yield - - - - - - - -
Capitalization / Revenue 2.67 x 4.55 x 5.77 x 6.55 x 4.44 x 4.14 x 3.86 x 3.63 x
EV / Revenue 2.74 x 3.85 x 5.72 x 6.46 x 3.45 x 3.24 x 2.52 x 1.98 x
EV / EBITDA -28.1 x 8.87 x 15.9 x 12.1 x 6.49 x 6.17 x 4.95 x 4.07 x
EV / FCF -13.7 x 8.2 x 20.2 x 18.9 x 10.8 x 7.01 x 6.92 x 4.86 x
FCF Yield -7.3% 12.2% 4.95% 5.3% 9.3% 14.3% 14.5% 20.6%
Price to Book 1.39 x 1.99 x 2.67 x 2.67 x 1.73 x 1.61 x 1.39 x 1.23 x
Nbr of stocks (in thousands) 43,881 44,441 45,037 45,577 46,994 44,366 - -
Reference price 2 88.08 151.8 216.1 278.1 219.9 255.1 255.1 255.1
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,449 1,483 1,686 1,936 2,328 2,732 2,935 3,116
EBITDA 1 -141.7 643.5 605.8 1,031 1,238 1,432 1,491 1,515
EBIT 1 -187.6 593.6 555.9 979.7 1,185 1,413 1,543 1,572
Operating Margin -12.95% 40.02% 32.98% 50.6% 50.91% 51.71% 52.57% 50.44%
Earnings before Tax (EBT) 1 -165 638.9 593.9 950.6 1,274 1,513 1,656 1,643
Net income 1 -104.5 514.8 475.8 727.3 984.8 1,184 1,293 1,312
Net margin -7.21% 34.71% 28.23% 37.56% 42.31% 43.33% 44.05% 42.11%
EPS 2 -2.390 11.54 10.06 15.00 19.81 24.54 26.48 26.73
Free Cash Flow 1 -290.3 696.4 477.4 663.7 747.6 1,261 1,068 1,269
FCF margin -20.04% 46.95% 28.32% 34.28% 32.12% 46.16% 36.37% 40.72%
FCF Conversion (EBITDA) - 108.22% 78.8% 64.37% 60.38% 88.03% 71.61% 83.73%
FCF Conversion (Net income) - 135.28% 100.34% 91.26% 75.91% 106.52% 82.57% 96.7%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 444.7 415.2 461.9 466.9 516 491.5 506.9 596.5 609.4 614.7 677.7 684.3 700.3 696.9 795.3
EBITDA 241.1 182.4 300.5 214.5 327.2 188.8 297.7 326.3 340.3 273.8 371.3 - - - -
EBIT 1 228.7 169.8 288 201.8 314.3 175.6 284.4 313.4 327 260.1 356.3 361.9 366.1 339 502.5
Operating Margin 51.43% 40.9% 62.35% 43.22% 60.91% 35.73% 56.11% 52.54% 53.66% 42.31% 52.57% 52.88% 52.28% 48.64% 63.18%
Earnings before Tax (EBT) 1 204.4 140.5 308.7 150.6 312.5 178.8 291.9 335.2 351.8 295.4 398.6 400.2 405.6 383.1 545.2
Net income 1 162.7 112.2 239.9 116 239.3 132.1 240.9 259.2 267.6 217.1 306.6 302.5 306.1 289.9 430.7
Net margin 36.59% 27.02% 51.94% 24.84% 46.38% 26.88% 47.52% 43.45% 43.91% 35.32% 45.24% 44.2% 43.71% 41.6% 54.16%
EPS 2 3.420 2.350 5.030 2.410 4.910 2.670 4.860 5.240 5.380 4.360 6.170 6.191 6.299 5.931 9.180
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 03/11/21 24/02/22 04/05/22 03/08/22 02/11/22 22/02/23 03/05/23 02/08/23 01/11/23 21/02/24 01/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 112 - - - - - - -
Net Cash position 1 - 1,035 94.8 161 2,294 2,480 3,935 5,148
Leverage (Debt/EBITDA) -0.7876 x - - - - - - -
Free Cash Flow 1 -290 696 477 664 748 1,261 1,068 1,269
ROE (net income / shareholders' equity) -3.75% 16.7% 12.9% 16.6% 18.3% 21.2% 15.1% 12.9%
ROA (Net income/ Total Assets) 15.6% 12.1% 9.85% 13% 14.9% 14.8% 13.7% 12.5%
Assets 1 -671.4 4,264 4,832 5,607 6,606 8,003 9,417 10,470
Book Value Per Share 2 63.40 76.40 81.00 104.0 127.0 158.0 183.0 208.0
Cash Flow per Share 2 -4.720 16.90 12.60 16.50 19.70 25.80 25.60 28.70
Capex 1 83.7 59.3 121 139 230 150 250 198
Capex / Sales 5.78% 4% 7.17% 7.17% 9.9% 5.49% 8.53% 6.37%
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
255.1 USD
Average target price
292.7 USD
Spread / Average Target
+14.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+17.39% 11.32B
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Financials United Therapeutics Corporation